TCR-JANUS 衔接蛋白实现双特异性靶向以克服 TCR-T 细胞治疗中的肿瘤异质性
TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy.
基于 T 细胞受体(TCR)的免疫疗法受限于肿瘤抗原异质性,后者常导致复发。
英文原题:Rapid generation of genetically engineered T cells for the treatment of virus-related cancers.
Rapid generation of genetically engineered T cells for the treatment of virus-related cancers.
本研究提供了一种适用于HLA-A11:01人群的HPV16特异性TCR,并展示了一种可应用于大规模筛选病毒特异性TCR的高效方法,进一步鼓励研究人员挖掘TCR-T细胞技术在治疗病毒相关癌症中的治疗潜力。
靶向病毒表位的T细胞受体(TCR)工程化T细胞的过继转移是治疗病毒相关癌症的一种有前景的方法。然而,高效鉴定T细胞表位及相应TCR仍具有挑战性。在此,我们报道了一种能够快速生成人乳头瘤病毒(HPV)特异性TCR-T细胞的工作流程。根据生物信息学分析,预测属于HPV16或HPV18的六种病毒蛋白表位对A11:01具有高亲和力。随后,分别用这六种抗原肽进行CTL诱导,并通过FACS分选抗原特异性T细胞。利用下一代测序确定这些病毒特异性T细胞的TCR克隆型。为提高TCR配对验证的效率,构建了一个包含116个TCR构建体的慢病毒载体文库,该文库由根据TCR库分析得出的优势TCR组成。之后,用肽池脉冲的抗原呈递细胞刺激TCR文库转导的T细胞,然后分选CD137阳性细胞并进行TCR库分析。推断并验证了排名靠前的TCR及相应抗原肽。通过该工作流程,鉴定出了一种靶向HPV16 E6 92-101的TCR。这些HPV16特异性TCR-T细胞在体外对HPV16阳性人宫颈癌细胞表现出高活性,并在小鼠模型中有效抑制肿瘤生长。本研究提供了一种适用于HLA-A11:01人群的HPV16特异性TCR,并展示了一种可应用于大规模筛选病毒特异性TCR的高效方法,进一步鼓励研究人员开发TCR-T细胞技术在治疗病毒相关癌症中的治疗潜力。
Adoptive transfer of T cell receptor (TCR)-engineered T cells targeting viral epitopes represents a promising approach for treating virus-related cancers. However, the efficient identification of epitopes for T cells and the corresponding TCR remains challenging. Here, we report a workflow permitting the rapid generation of human papillomavirus (HPV)-specific TCR-T cells. Six epitopes of viral proteins belonged to HPV16 or HPV18 were predicted to have high affinity to A11:01 according to bioinformatic analysis. Subsequently, CTL induction were performed with these six antigen peptides separately, and antigen-specific T cells were sorted by FACS. TCR clonotypes of these virus-specific T cells were determined using next-generation sequencing. To improve the efficiency of TCR pair validation, a lentiviral vector library containing 116 TCR constructs was generated that consisted of predominant TCRs according to TCR repertoire analysis. Later, TCR library transduced T cells were simulated with peptide pool-pulsed antigen-presenting cells, then CD137-positive cells were sorted and subjected to TCR repertoire analysis. The top-hit TCRs and corresponding antigen peptides were deduced and validated. Through this workflow, a TCR targeting the E6 92-101 of HPV16 was identified. These HPV16-specific TCR-T cells showed high activity towards HPV16-positive human cervical cancer cells in vitro and efficiently repressed tumor growth in a murine model. This study provides a HPV16-specific TCR fitted to the HLA-A11:01 population, and exemplifies an efficient approach that can be applied in large-scale screening of virus-specific TCRs, further encouraging researchers to exploit the therapeutic potential of the TCR-T cell technique in treating virus-related cancers.
MEMBER ACCOUNT
登录成功会直接打开下一页。